Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 520

1.

Recombinant Decorin Fusion Protein Attenuates Murine Abdominal Aortic Aneurysm Formation and Rupture.

Shen Y, Russo V, Zeglinski MR, Sellers SL, Wu Z, Oram C, Santacruz S, Merkulova Y, Turner C, Tauh K, Zhao H, Bozin T, Bohunek L, Zeng H, Seidman MA, Bleackley RC, McManus BM, Ruoslahti E, Järvinen TAH, Granville DJ.

Sci Rep. 2017 Nov 20;7(1):15857. doi: 10.1038/s41598-017-16194-8.

2.

Identification of a peptide recognizing cerebrovascular changes in mouse models of Alzheimer's disease.

Mann AP, Scodeller P, Hussain S, Braun GB, Mölder T, Toome K, Ambasudhan R, Teesalu T, Lipton SA, Ruoslahti E.

Nat Commun. 2017 Nov 10;8(1):1403. doi: 10.1038/s41467-017-01096-0.

3.

Precision Targeting of Tumor Macrophages with a CD206 Binding Peptide.

Scodeller P, Simón-Gracia L, Kopanchuk S, Tobi A, Kilk K, Säälik P, Kurm K, Squadrito ML, Kotamraju VR, Rinken A, De Palma M, Ruoslahti E, Teesalu T.

Sci Rep. 2017 Nov 7;7(1):14655. doi: 10.1038/s41598-017-14709-x.

4.

Selective Targeting of a Novel Vasodilator to the Uterine Vasculature to Treat Impaired Uteroplacental Perfusion in Pregnancy.

Cureton N, Korotkova I, Baker B, Greenwood S, Wareing M, Kotamraju VR, Teesalu T, Cellesi F, Tirelli N, Ruoslahti E, Aplin JD, Harris LK.

Theranostics. 2017 Aug 29;7(15):3715-3731. doi: 10.7150/thno.19678. eCollection 2017.

5.

New Insights into "Permeability" as in the Enhanced Permeability and Retention Effect of Cancer Nanotherapeutics.

Nel A, Ruoslahti E, Meng H.

ACS Nano. 2017 Oct 24;11(10):9567-9569. doi: 10.1021/acsnano.7b07214. No abstract available.

PMID:
29065443
6.

Vascular changes in tumors resistant to a vascular disrupting nanoparticle treatment.

Sharma S, Mann AP, Mölder T, Kotamraju VR, Mattrey R, Teesalu T, Ruoslahti E.

J Control Release. 2017 Dec 28;268:49-56. doi: 10.1016/j.jconrel.2017.10.006. Epub 2017 Oct 13.

PMID:
29030222
7.

In vivo cation exchange in quantum dots for tumor-specific imaging.

Liu X, Braun GB, Qin M, Ruoslahti E, Sugahara KN.

Nat Commun. 2017 Aug 24;8(1):343. doi: 10.1038/s41467-017-00153-y.

8.

Porous Silicon Nanoparticle Delivery of Tandem Peptide Anti-Infectives for the Treatment of Pseudomonas aeruginosa Lung Infections.

Kwon EJ, Skalak M, Bertucci A, Braun G, Ricci F, Ruoslahti E, Sailor MJ, Bhatia SN.

Adv Mater. 2017 Sep;29(35). doi: 10.1002/adma.201701527. Epub 2017 Jul 12.

PMID:
28699173
9.

Ratiometric in vivo auditioning of targeted silver nanoparticles.

Toome K, Willmore AA, Paiste P, Tobi A, Sugahara KN, Kirsimäe K, Ruoslahti E, Braun GB, Teesalu T.

Nanoscale. 2017 Jul 20;9(28):10094-10100. doi: 10.1039/c7nr04056c.

PMID:
28695222
10.

Correction for Fogal et al., "Mitochondrial p32 Protein Is a Critical Regulator of Tumor Metabolism via Maintenance of Oxidative Phosphorylation".

Fogal V, Richardson AD, Karmali PP, Scheffler IE, Smith JW, Ruoslahti E.

Mol Cell Biol. 2017 Jun 29;37(14). pii: e00137-17. doi: 10.1128/MCB.00137-17. Print 2017 Jul 15. No abstract available.

11.

Targeting of p32 in peritoneal carcinomatosis with intraperitoneal linTT1 peptide-guided pro-apoptotic nanoparticles.

Hunt H, Simón-Gracia L, Tobi A, Kotamraju VR, Sharma S, Nigul M, Sugahara KN, Ruoslahti E, Teesalu T.

J Control Release. 2017 Aug 28;260:142-153. doi: 10.1016/j.jconrel.2017.06.005. Epub 2017 Jun 8.

PMID:
28603028
12.

Access granted: iRGD helps silicasome-encased drugs breach the tumor barrier.

Ruoslahti E.

J Clin Invest. 2017 May 1;127(5):1622-1624. doi: 10.1172/JCI93955. Epub 2017 Apr 17.

13.

Tumor-Penetrating Nanosystem Strongly Suppresses Breast Tumor Growth.

Sharma S, Kotamraju VR, Mölder T, Tobi A, Teesalu T, Ruoslahti E.

Nano Lett. 2017 Mar 8;17(3):1356-1364. doi: 10.1021/acs.nanolett.6b03815. Epub 2017 Feb 17.

PMID:
28178415
14.

Mechanisms and Barriers in Cancer Nanomedicine: Addressing Challenges, Looking for Solutions.

Anchordoquy TJ, Barenholz Y, Boraschi D, Chorny M, Decuzzi P, Dobrovolskaia MA, Farhangrazi ZS, Farrell D, Gabizon A, Ghandehari H, Godin B, La-Beck NM, Ljubimova J, Moghimi SM, Pagliaro L, Park JH, Peer D, Ruoslahti E, Serkova NJ, Simberg D.

ACS Nano. 2017 Jan 24;11(1):12-18. doi: 10.1021/acsnano.6b08244. Epub 2017 Jan 9.

15.

Composite Porous Silicon-Silver Nanoparticles as Theranostic Antibacterial Agents.

Kim T, Braun GB, She ZG, Hussain S, Ruoslahti E, Sailor MJ.

ACS Appl Mater Interfaces. 2016 Nov 9;8(44):30449-30457. Epub 2016 Oct 27.

PMID:
27754645
16.

iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes.

Simón-Gracia L, Hunt H, Scodeller P, Gaitzsch J, Kotamraju VR, Sugahara KN, Tammik O, Ruoslahti E, Battaglia G, Teesalu T.

Biomaterials. 2016 Oct;104:247-57. doi: 10.1016/j.biomaterials.2016.07.023. Epub 2016 Jul 20.

17.

Tumor-Targeted Multimodal Optical Imaging with Versatile Cadmium-Free Quantum Dots.

Liu X, Braun GB, Zhong H, Hall DJ, Han W, Qin M, Zhao C, Wang M, She ZG, Cao C, Sailor MJ, Stallcup WB, Ruoslahti E, Sugahara KN.

Adv Funct Mater. 2016 Jan 13;26(2):267-276. Epub 2015 Dec 2.

18.

Plaque-penetrating peptide inhibits development of hypoxic atherosclerotic plaque.

She ZG, Hamzah J, Kotamraju VR, Pang HB, Jansen S, Ruoslahti E.

J Control Release. 2016 Sep 28;238:212-220. doi: 10.1016/j.jconrel.2016.07.020. Epub 2016 Jul 15.

PMID:
27423327
19.

Tumor-homing peptides as tools for targeted delivery of payloads to the placenta.

King A, Ndifon C, Lui S, Widdows K, Kotamraju VR, Agemy L, Teesalu T, Glazier JD, Cellesi F, Tirelli N, Aplin JD, Ruoslahti E, Harris LK.

Sci Adv. 2016 May 6;2(5):e1600349. doi: 10.1126/sciadv.1600349. eCollection 2016 May.

20.

Self-Sealing Porous Silicon-Calcium Silicate Core-Shell Nanoparticles for Targeted siRNA Delivery to the Injured Brain.

Kang J, Joo J, Kwon EJ, Skalak M, Hussain S, She ZG, Ruoslahti E, Bhatia SN, Sailor MJ.

Adv Mater. 2016 Sep;28(36):7962-7969. doi: 10.1002/adma.201600634. Epub 2016 Jul 6.

PMID:
27383373
21.

A peptide for targeted, systemic delivery of imaging and therapeutic compounds into acute brain injuries.

Mann AP, Scodeller P, Hussain S, Joo J, Kwon E, Braun GB, Mölder T, She ZG, Kotamraju VR, Ranscht B, Krajewski S, Teesalu T, Bhatia S, Sailor MJ, Ruoslahti E.

Nat Commun. 2016 Jun 28;7:11980. doi: 10.1038/ncomms11980.

22.

Urokinase-controlled tumor penetrating peptide.

Braun GB, Sugahara KN, Yu OM, Kotamraju VR, Mölder T, Lowy AM, Ruoslahti E, Teesalu T.

J Control Release. 2016 Jun 28;232:188-95. doi: 10.1016/j.jconrel.2016.04.027. Epub 2016 Apr 19.

23.

Tumor penetrating peptides for improved drug delivery.

Ruoslahti E.

Adv Drug Deliv Rev. 2017 Feb;110-111:3-12. doi: 10.1016/j.addr.2016.03.008. Epub 2016 Apr 1. Review.

24.

New p32/gC1qR Ligands for Targeted Tumor Drug Delivery.

Paasonen L, Sharma S, Braun GB, Kotamraju VR, Chung TD, She ZG, Sugahara KN, Yliperttula M, Wu B, Pellecchia M, Ruoslahti E, Teesalu T.

Chembiochem. 2016 Apr 1;17(7):570-5. doi: 10.1002/cbic.201500564. Epub 2016 Feb 19.

25.

Paclitaxel-Loaded Polymersomes for Enhanced Intraperitoneal Chemotherapy.

Simón-Gracia L, Hunt H, Scodeller PD, Gaitzsch J, Braun GB, Willmore AM, Ruoslahti E, Battaglia G, Teesalu T.

Mol Cancer Ther. 2016 Apr;15(4):670-9. doi: 10.1158/1535-7163.MCT-15-0713-T. Epub 2016 Feb 15.

26.

Synthesis of linear and cyclic peptide-PEG-lipids for stabilization and targeting of cationic liposome-DNA complexes.

Ewert KK, Kotamraju VR, Majzoub RN, Steffes VM, Wonder EA, Teesalu T, Ruoslahti E, Safinya CR.

Bioorg Med Chem Lett. 2016 Mar 15;26(6):1618-1623. doi: 10.1016/j.bmcl.2016.01.079. Epub 2016 Feb 4.

27.

Targeted silver nanoparticles for ratiometric cell phenotyping.

Willmore AM, Simón-Gracia L, Toome K, Paiste P, Kotamraju VR, Mölder T, Sugahara KN, Ruoslahti E, Braun GB, Teesalu T.

Nanoscale. 2016 Apr 28;8(17):9096-101. doi: 10.1039/c5nr07928d.

28.

Neuropilin-1 and heparan sulfate proteoglycans cooperate in cellular uptake of nanoparticles functionalized by cationic cell-penetrating peptides.

Pang HB, Braun GB, Ruoslahti E.

Sci Adv. 2015 Nov 6;1(10):e1500821. doi: 10.1126/sciadv.1500821. eCollection 2015 Nov.

29.

A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis.

Sugahara KN, Scodeller P, Braun GB, de Mendoza TH, Yamazaki CM, Kluger MD, Kitayama J, Alvarez E, Howell SB, Teesalu T, Ruoslahti E, Lowy AM.

J Control Release. 2015 Aug 28;212:59-69. doi: 10.1016/j.jconrel.2015.06.009. Epub 2015 Jun 11.

30.

Gated Luminescence Imaging of Silicon Nanoparticles.

Joo J, Liu X, Kotamraju VR, Ruoslahti E, Nam Y, Sailor MJ.

ACS Nano. 2015 Jun 23;9(6):6233-41. doi: 10.1021/acsnano.5b01594. Epub 2015 Jun 9.

31.

Nanoparticles coated with the tumor-penetrating peptide iRGD reduce experimental breast cancer metastasis in the brain.

Hamilton AM, Aidoudi-Ahmed S, Sharma S, Kotamraju VR, Foster PJ, Sugahara KN, Ruoslahti E, Rutt BK.

J Mol Med (Berl). 2015 Sep;93(9):991-1001. doi: 10.1007/s00109-015-1279-x. Epub 2015 Apr 14.

32.

Selection strategies for anticancer antibody discovery: searching off the beaten path.

Sánchez-Martín D, Sørensen MD, Lykkemark S, Sanz L, Kristensen P, Ruoslahti E, Álvarez-Vallina L.

Trends Biotechnol. 2015 May;33(5):292-301. doi: 10.1016/j.tibtech.2015.02.008. Epub 2015 Mar 26. Review.

33.

Increasing Tumor Accessibility with Conjugatable Disulfide-Bridged Tumor-Penetrating Peptides for Cancer Diagnosis and Treatment.

Kotamraju VR, Sharma S, Kolhar P, Agemy L, Pavlovich J, Ruoslahti E.

Breast Cancer (Auckl). 2016 Jun 27;9(Suppl 2):79-87. doi: 10.4137/BCBCR.S29426. eCollection 2015.

34.

Tumor-penetrating iRGD peptide inhibits metastasis.

Sugahara KN, Braun GB, de Mendoza TH, Kotamraju VR, French RP, Lowy AM, Teesalu T, Ruoslahti E.

Mol Cancer Ther. 2015 Jan;14(1):120-8. doi: 10.1158/1535-7163.MCT-14-0366. Epub 2014 Nov 12.

35.

Reprogramming human retinal pigmented epithelial cells to neurons using recombinant proteins.

Hu Q, Chen R, Teesalu T, Ruoslahti E, Clegg DO.

Stem Cells Transl Med. 2014 Dec;3(12):1526-34. doi: 10.5966/sctm.2014-0038. Epub 2014 Oct 8.

36.

An endocytosis pathway initiated through neuropilin-1 and regulated by nutrient availability.

Pang HB, Braun GB, Friman T, Aza-Blanc P, Ruidiaz ME, Sugahara KN, Teesalu T, Ruoslahti E.

Nat Commun. 2014 Oct 3;5:4904. doi: 10.1038/ncomms5904.

37.

Clot-targeted micellar formulation improves anticoagulation efficacy of bivalirudin.

She ZG, Liu X, Kotamraju VR, Ruoslahti E.

ACS Nano. 2014 Oct 28;8(10):10139-49. doi: 10.1021/nn502947b. Epub 2014 Oct 7.

PMID:
25270510
38.

Quantity and accessibility for specific targeting of receptors in tumours.

Hussain S, Rodriguez-Fernandez M, Braun GB, Doyle FJ 3rd, Ruoslahti E.

Sci Rep. 2014 Jun 10;4:5232. doi: 10.1038/srep05232.

39.

Etchable plasmonic nanoparticle probes to image and quantify cellular internalization.

Braun GB, Friman T, Pang HB, Pallaoro A, Hurtado de Mendoza T, Willmore AM, Kotamraju VR, Mann AP, She ZG, Sugahara KN, Reich NO, Teesalu T, Ruoslahti E.

Nat Mater. 2014 Sep;13(9):904-11. doi: 10.1038/nmat3982. Epub 2014 Jun 8.

40.

Targeted Antiscarring Therapy for Tissue Injuries.

Järvinen TA, Ruoslahti E.

Adv Wound Care (New Rochelle). 2013 Mar;2(2):50-54. Review.

41.

(64)Cu-labeled LyP-1-dendrimer for PET-CT imaging of atherosclerotic plaque.

Seo JW, Baek H, Mahakian LM, Kusunose J, Hamzah J, Ruoslahti E, Ferrara KW.

Bioconjug Chem. 2014 Feb 19;25(2):231-9. doi: 10.1021/bc400347s. Epub 2014 Jan 31.

42.

A novel vascular homing peptide strategy to selectively enhance pulmonary drug efficacy in pulmonary arterial hypertension.

Toba M, Alzoubi A, O'Neill K, Abe K, Urakami T, Komatsu M, Alvarez D, Järvinen TA, Mann D, Ruoslahti E, McMurtry IF, Oka M.

Am J Pathol. 2014 Feb;184(2):369-75. doi: 10.1016/j.ajpath.2013.10.008. Epub 2014 Jan 6.

43.

A free cysteine prolongs the half-life of a homing peptide and improves its tumor-penetrating activity.

Pang HB, Braun GB, She ZG, Kotamraju VR, Sugahara KN, Teesalu T, Ruoslahti E.

J Control Release. 2014 Feb 10;175:48-53. doi: 10.1016/j.jconrel.2013.12.006. Epub 2013 Dec 15.

44.

Nanoparticle amplification via photothermal unveiling of cryptic collagen binding sites.

Lo JH, von Maltzahn G, Douglass J, Park JH, Sailor MJ, Ruoslahti E, Bhatia SN.

J Mater Chem B. 2013 Oct 21;1(39):5235-5240. Epub 2013 Jun 14.

45.

Supramolecular nanoparticles that target phosphoinositide-3-kinase overcome insulin resistance and exert pronounced antitumor efficacy.

Kulkarni AA, Roy B, Rao PS, Wyant GA, Mahmoud A, Ramachandran M, Sengupta P, Goldman A, Kotamraju VR, Basu S, Mashelkar RA, Ruoslahti E, Dinulescu DM, Sengupta S.

Cancer Res. 2013 Dec 1;73(23):6987-97. doi: 10.1158/0008-5472.CAN-12-4477. Epub 2013 Oct 11.

46.

In vivo selection of tumor-specific antibodies.

Sánchez-Martín D, Sanz L, Ruoslahti E, Alvarez-Vallina L.

Oncotarget. 2013 Oct;4(10):1547. No abstract available.

47.

Tumor-penetrating peptides.

Teesalu T, Sugahara KN, Ruoslahti E.

Front Oncol. 2013 Aug 27;3:216. doi: 10.3389/fonc.2013.00216. eCollection 2013.

48.

Proapoptotic peptide-mediated cancer therapy targeted to cell surface p32.

Agemy L, Kotamraju VR, Friedmann-Morvinski D, Sharma S, Sugahara KN, Ruoslahti E.

Mol Ther. 2013 Dec;21(12):2195-204. doi: 10.1038/mt.2013.191. Epub 2013 Aug 20. Erratum in: Mol Ther. 2014 Nov;22(11):2013.

49.

Proteasome activator complex PA28 identified as an accessible target in prostate cancer by in vivo selection of human antibodies.

Sánchez-Martín D, Martínez-Torrecuadrada J, Teesalu T, Sugahara KN, Alvarez-Cienfuegos A, Ximénez-Embún P, Fernández-Periáñez R, Martín MT, Molina-Privado I, Ruppen-Cañás I, Blanco-Toribio A, Cañamero M, Cuesta AM, Compte M, Kremer L, Bellas C, Alonso-Camino V, Guijarro-Muñoz I, Sanz L, Ruoslahti E, Alvarez-Vallina L.

Proc Natl Acad Sci U S A. 2013 Aug 20;110(34):13791-6. doi: 10.1073/pnas.1300013110. Epub 2013 Aug 5.

50.

Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium.

Kolhar P, Anselmo AC, Gupta V, Pant K, Prabhakarpandian B, Ruoslahti E, Mitragotri S.

Proc Natl Acad Sci U S A. 2013 Jun 25;110(26):10753-8. doi: 10.1073/pnas.1308345110. Epub 2013 Jun 10.

Supplemental Content

Loading ...
Support Center